Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone , with the greatest clinical benefit in BRCA-mutated patients , and had an acceptable and manageable tolerability profile .